Company: Alembic Ltd
Sector: Real Estate & Investment Holding
Basic Details
-
Market Cap: ~₹2,000 Crores (as of end March 2026)
-
Current Price: ~₹79 (as of end March 2026)
Financial Highlights (FY25 Consolidated)
-
Revenue: ₹222 Crores
-
Consolidated PAT: ₹311 Crores
-
Real Estate Segment PAT: ~₹70 Crores (approx. 90% of operating profits)
-
Debt-to-Equity: 0.006 (Virtually debt-free)
-
Cash & Bank Balance: ~₹52 Crores
Sum of the Parts (SOTP) Valuation
To understand the valuation gap, we must break down the company into its constituent parts. Based on current market benchmarks, the “Intrinsic NAV” is significantly higher than the current market price.
| Business Component | Metric (FY25/Current) | Valuation Basis | Estimated Value (₹ Cr) |
|---|---|---|---|
| Listed Holdings (APL) | 28.54% stake in APL | Market Value (Mar 2026) | ₹3,895.00 |
| Listed Holdings (Paushak) | 19.07% stake in Paushak | Market Value (Mar 2026) | ₹182.93 |
| Real Estate Business | ₹70 Cr PAT (FY25) | 24x Industry Median PE | ₹1,680.00 |
| Cash & Liquid Assets | Standalone Cash | Book Value | ₹52.00 |
| Total Asset Value (NAV) | ₹5,809.93 | ||
| Intrinsic Value Per Share | ~₹226.00 |
The Valuation Gap:
At a current price of ~₹79, the stock is trading at a 65% discount to its intrinsic SOTP value. Even if we apply a conservative 60% holding company discount to the listed investments (reducing their value to ~₹1,631 Cr), the combined value of Investments + Real Estate would still be ~₹3,363 Cr, or ₹131 per share (a 65% upside from current levels).
Management Quality & Governance
-
Track Record: The Amin family has managed the group for over a century. However, governance skeptics point to the 99.53% institutional dissent in 2025 regarding the succession and remuneration plan for the promoter family.
-
Integrity Metrics: Promoters have maintained Zero Pledging for over a decade. The group is recognized for significant philanthropy, managing hospitals and non-profit schools for 50+ years.
Investment Thesis
Positives:
-
Real Estate Yardstick: Valuing the RE business at the industry median PE of 24x yields a valuation of ~₹1,700 Crores. This alone covers ~83% of the current market cap, effectively leaving the ₹4,078 Cr worth of pharma holdings as a “free” bonus.
-
Asset Monetization: The company owns a 102-acre premium land bank in Vadodara. With real estate sales growing at a 16% CAGR, the “burn rate” of this land bank provides long-term visibility.
-
Dividend Yield: Consistent payout of ₹2.40/share offers a 3.03% yield, providing a floor to the stock price.
Concerns:
-
Holding Company Discount: Value unlocking remains the “elephant in the room.” Without a spin-off or buyback, the market may continue to penalize the stock despite the asset heavy-balance sheet.
-
Governance Overhang: High commissions to non-executive promoter directors remain a friction point for institutional investors.
Growth Catalysts
-
Monetization of Land: Ongoing real-estate developments and projects could provide a significant cash flow delta.
-
Re-rating of the Realty Segment: If the market starts viewing Alembic as a “pure-play” developer rather than a “pharma holding co,” the PE could expand toward the industry median of 24x.
Suggestion (for discussion)
One gap I noticed: No regular concalls / structured investor communication. Would be useful if management:
-
Starts annual concalls (at least)
-
Shares clarity on:
-
Real estate roadmap
-
Capital allocation
-
View on holding company discount
-
Disclosures: Invested. Added more recently. Possibly biased.
Disclaimer: This analysis is for educational purposes only. Small/midcap holding companies often trade at deep discounts for years; this is not a recommendation to buy or sell. Please conduct your own due diligence or consult a SEBI-registered advisor.